Search Result

Results for "

PKA+inhibitor

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Akt (2) Biochemical Assay Reagents (1) CDK (2) Drug Intermediate (1) Epigenetic Reader Domain (2) Flavivirus (2) G Protein-coupled Receptor Kinase (GRK) (2) LIM Kinase (LIMK) (2) MARCKS (1) Phosphodiesterase (PDE) (1) PKA (14) PKC (1) ROCK (2)
By Research Areas:	Cancer (6) Endocrinology (2) Infection (2) Inflammation/Immunology (1) Metabolic Disease (1) Neurological Disease (7)

Inhibitors & Agonists

Biochemical Assay Reagents

Peptides

Natural
Products

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-N6789

KT5720 4 Publications Verification	PKA	Neurological Disease Cancer
KT5720 is a potent, cell-permeable, specific, reversible and ATP-competitive *PKA* inhibitor (IC₅₀=3.3 μM). KT5720 is effective in reversing MDR1-mediated multidrug resistance. KT5720 also reduces the excitability of dorsal root ganglion (DRG) neurons by attenuating Hyperpolarization-activated cyclic nucleotide-gated (HCN) channel activity and reducing intracellular Ca2 ⁺ concentrations. KT5720 can be used in the study of haematological malignancies as well as HCN and DRG neuron-related diseases .

HY-P1291

PKI 14-22 amide,myristoylated 3 Publications Verification	PKA Epigenetic Reader Domain Flavivirus	Infection Neurological Disease
PKI 14-22 amide, myristoylated is a selective, cAMP-dependent, competitive *PKA* inhibitor with K_i=~36 nM. The myristoylation modification of PKI 14-22 amide, myristoylated makes it more permeable to cell membranes and blood-brain barriers than the precursor molecule. PKI 14-22 amide, myristoylated can block the phosphorylation of cAMP-dependent downstream targets (such as CREB). PKI 14-22 amide, myristoylated can prevent the development of morphine analgesic tolerance in mice, and also inhibits protein translation and negative-strand RNA synthesis of Zika virus. PKI 14-22 amide, myristoylated can be used in research fields such as opioid tolerance mechanisms and antiviral drugs .

HY-P1290

PKA Inhibitor Fragment (6-22) amide 5 Publications Verification PKI-(6-22)-amide	PKA	Neurological Disease
PKA Inhibitor Fragment (6-22) amide is a highly potent and specific competitive inhibitor of PKA, with K_i values of 1.7 nM and 1.6 nM against human and bovine PKA catalytic subunits, respectively. The IC₅₀ of PKA Inhibitor Fragment (6-22) amide targeting bovine PKA is 8.6 nM. PKA Inhibitor Fragment (6-22) amide effectively abolishes PKA activity in mouse brain and spinal cord, and exerts in vivo efficacy via intracerebroventricular administration. PKA Inhibitor Fragment (6-22) amide significantly reverses low-dose morphine analgesic tolerance in mice and blocks photoaffinity labeling of cAMP-dependent protein kinase. PKA Inhibitor Fragment (6-22) amide can be applied to research in fields related to the mechanism of morphine analgesic tolerance and skin wound healing .

HY-P1290A

PKA Inhibitor Fragment (6-22) amide TFA 5 Publications Verification PKI-(6-22)-amide TFA	PKA	Neurological Disease
PKA Inhibitor Fragment (6-22) amide TFA is an inhibitor of cAMP-dependent protein kinase A (PKA), with a K_i of 2.8 nM. PKA Inhibitor Fragment (6-22) amide TFA can significantly reverse antinociceptive tolerance in mice .

HY-W001242

1-(Tetrahydropyran-2-yl)-1H-pyrazole-5-boronic acid pinacol ester	Biochemical Assay Reagents Drug Intermediate	Others
1-(Tetrahydropyran-2-yl)-1H-pyrazole-5-boronic acid pinacol ester is a pharmaceutical intermediate used in the synthesis of naphthyl *FXIa/PKa** inhibitors* .

HY-12659

LX7101 3 Publications Verification	LIM Kinase (LIMK) ROCK PKA	Endocrinology
LX7101 is a potent LIM-kinase, ROCK and *PKA* inhibitor with IC₅₀s of 24 nM, 1.6 nM, 10 nM and <1 nM for LIMK1, LIMK2, ROCK2 and PKA, respectively. LX7101 proves significantly selective for LIMK2 with IC₅₀ values of 4.3 nM and 32 nM for LIMK2 and LIMK1 at 2 μM ATP, respectively. LX7101 has the potential for ocular hypertension and associated glaucoma research .

HY-P1291A

PKI 14-22 amide,myristoylated TFA 3 Publications Verification	PKA Epigenetic Reader Domain Flavivirus	Infection Neurological Disease
PKI 14-22 amide, myristoylated TFA is a selective, cAMP-dependent, competitive *PKA* inhibitor with K_i=~36 nM. The myristoylation modification of PKI 14-22 amide, myristoylated TFA makes it more permeable to cell membranes and blood-brain barriers than the precursor molecule. PKI 14-22 amide, myristoylated TFA can block the phosphorylation of cAMP-dependent downstream targets (such as CREB). PKI 14-22 amide, myristoylated TFA can prevent the development of analgesic tolerance in mice, and also inhibits protein translation and negative-strand RNA synthesis of Zika virus. PKI 14-22 amide, myristoylated TFA can be used in research fields such as opioid tolerance mechanisms and antiviral drugs .

HY-108047

MK-0873	Phosphodiesterase (PDE)	Metabolic Disease Inflammation/Immunology
MK-0873 is a selective phosphodiesterase-4 (PDE4) inhibitor. MK-0873 increases intracellular levels of cyclic adenosine phosphate (cAMP) by inhibiting the activity of the PDE4 enzyme and subsequently activates protein kinase A (PKA). Activated PKA inhibits the activity of inflammatory cells and leads to direct relaxation of airway smooth muscle. MK-0873 can be used in studies of chronic obstructive pulmonary disease (COPD) .

HY-123520

GSK299115A	G Protein-coupled Receptor Kinase (GRK) PKA	Cancer
GSK299115A is a G Protein-coupled Receptor Kinase (GRK) and *PKA* inhibitor .

HY-121197

Balanol Ophiocordin; Azepinostatin	MARCKS PKA PKC	Others
Balanol (Ophiocordin; Azepinostatin) is a potent and ATP competitive *PKC/PKA* inhibitor against human PKC isozymes α, β-I, β-II, γ, δ, ε, η (IC₅₀s=4-9 nM) and ζ (IC₅₀=150 nM). Balanol also blocks the phosphorylation of cyclic AMP response element-binding protein (CREB) and myristoylated alanine-rich C kinase substrate (MARCKS). Balanol can be isolated from the fungus Verticillium balanoides .

HY-P3929A

PKI (14-24)amide TFA 1 Publications Verification	PKA	Cancer
PKI (14-24)amide TFA is a potent *PKA* inhibitor. PKI (14-24)amide strongly inhibited cyclic AMP-dependent protein kinase activity in the cell homogenate .

HY-148868A

Akt1&PKA-IN-2	Akt CDK	Cancer
Akt1&PKA-IN-2 (Compound R-29) is a AKT1 and *PKA* inhibitor with selectivity for CDK2, with IC₅₀ values of 0.007 and 0.01 μM, respectively. Akt1&PKA-IN-2 is applicable for cancer research .

HY-P3930

PKI (5-24),amide IP20-amide	PKA	Neurological Disease
PKI (5-24),amide (IP20-amide) is a 20-residue peptide that corresponds to the active portion of the heat-stable inhibitor protein of cAMP-dependent protein kinase. PKI (5-24),amide is a potent cAMP-dependent protein kinase (PKA) (PKA) inhibitor with a K_i of 2.3 nM .

HY-148868

Akt1&PKA-IN-1	Akt PKA CDK	Others
Akt1&PKA-IN-1 is a potent dual *Akt/PKA* inhibitor with IC₅₀ values of 0.03 , 0.11 μM, and 9.8 μM for PKAa, Akt, and CDK2, respectively. Akt1&PKA-IN-1 is selective for cyclin-dependent kinase 2 (CDK2) .

HY-P3929

PKI (14-24)amide	PKA	Cancer
PKI (14-24)amide is a potent *PKA* inhibitor. PKI (14-24)amide strongly inhibited cyclic AMP-dependent protein kinase activity in the cell homogenate .

HY-119232

GSK466317A	PKA G Protein-coupled Receptor Kinase (GRK)	Neurological Disease Cancer
GSK466317A is a *PKA* inhibitor, with an IC₅₀ of 12.59 μM. GSK466317A also inhibits GRK1, GRK2, and GRK5, with IC₅₀s of 1000, 31.62, and 39.81 μM, respectively .

HY-12659B

LX7101 monohydrochloride	LIM Kinase (LIMK) ROCK PKA	Endocrinology
LX7101 monohydrochloride is a potent LIM-kinase, ROCK and *PKA* inhibitor with IC₅₀s of 24 nM, 1.6 nM, 10 nM and <1 nM for LIMK1, LIMK2, ROCK2 and PKA, respectively. LX7101 monohydrochloride proves significantly selective for LIMK2 with IC₅₀ values of 4.3 nM and 32 nM for LIMK2 and LIMK1 at 2 μM ATP, respectively. LX7101 monohydrochloride has the potential for ocular hypertension and associated glaucoma research .

1-(Tetrahydropyran-2-yl)-1H-pyrazole-5-boronic acid pinacol ester	Biochemical Assay Reagents
1-(Tetrahydropyran-2-yl)-1H-pyrazole-5-boronic acid pinacol ester is a pharmaceutical intermediate used in the synthesis of naphthyl *FXIa/PKa** inhibitors* .

Cat. No.	Product Name	Target	Research Area

HY-P1291

PKI 14-22 amide,myristoylated 3 Publications Verification	PKA Epigenetic Reader Domain Flavivirus	Infection Neurological Disease
PKI 14-22 amide, myristoylated is a selective, cAMP-dependent, competitive *PKA* inhibitor with K_i=~36 nM. The myristoylation modification of PKI 14-22 amide, myristoylated makes it more permeable to cell membranes and blood-brain barriers than the precursor molecule. PKI 14-22 amide, myristoylated can block the phosphorylation of cAMP-dependent downstream targets (such as CREB). PKI 14-22 amide, myristoylated can prevent the development of morphine analgesic tolerance in mice, and also inhibits protein translation and negative-strand RNA synthesis of Zika virus. PKI 14-22 amide, myristoylated can be used in research fields such as opioid tolerance mechanisms and antiviral drugs .

HY-P1290

PKA Inhibitor Fragment (6-22) amide 5 Publications Verification PKI-(6-22)-amide	PKA	Neurological Disease
PKA Inhibitor Fragment (6-22) amide is a highly potent and specific competitive inhibitor of PKA, with K_i values of 1.7 nM and 1.6 nM against human and bovine PKA catalytic subunits, respectively. The IC₅₀ of PKA Inhibitor Fragment (6-22) amide targeting bovine PKA is 8.6 nM. PKA Inhibitor Fragment (6-22) amide effectively abolishes PKA activity in mouse brain and spinal cord, and exerts in vivo efficacy via intracerebroventricular administration. PKA Inhibitor Fragment (6-22) amide significantly reverses low-dose morphine analgesic tolerance in mice and blocks photoaffinity labeling of cAMP-dependent protein kinase. PKA Inhibitor Fragment (6-22) amide can be applied to research in fields related to the mechanism of morphine analgesic tolerance and skin wound healing .

HY-P1290A

PKA Inhibitor Fragment (6-22) amide TFA 5 Publications Verification PKI-(6-22)-amide TFA	PKA	Neurological Disease
PKA Inhibitor Fragment (6-22) amide TFA is an inhibitor of cAMP-dependent protein kinase A (PKA), with a K_i of 2.8 nM. PKA Inhibitor Fragment (6-22) amide TFA can significantly reverse antinociceptive tolerance in mice .

HY-P1291A

PKI 14-22 amide,myristoylated TFA 3 Publications Verification	PKA Epigenetic Reader Domain Flavivirus	Infection Neurological Disease
PKI 14-22 amide, myristoylated TFA is a selective, cAMP-dependent, competitive *PKA* inhibitor with K_i=~36 nM. The myristoylation modification of PKI 14-22 amide, myristoylated TFA makes it more permeable to cell membranes and blood-brain barriers than the precursor molecule. PKI 14-22 amide, myristoylated TFA can block the phosphorylation of cAMP-dependent downstream targets (such as CREB). PKI 14-22 amide, myristoylated TFA can prevent the development of analgesic tolerance in mice, and also inhibits protein translation and negative-strand RNA synthesis of Zika virus. PKI 14-22 amide, myristoylated TFA can be used in research fields such as opioid tolerance mechanisms and antiviral drugs .

HY-P3929A

PKI (14-24)amide TFA 1 Publications Verification	PKA	Cancer
PKI (14-24)amide TFA is a potent *PKA* inhibitor. PKI (14-24)amide strongly inhibited cyclic AMP-dependent protein kinase activity in the cell homogenate .

HY-P3930

PKI (5-24),amide IP20-amide	PKA	Neurological Disease
PKI (5-24),amide (IP20-amide) is a 20-residue peptide that corresponds to the active portion of the heat-stable inhibitor protein of cAMP-dependent protein kinase. PKI (5-24),amide is a potent cAMP-dependent protein kinase (PKA) (PKA) inhibitor with a K_i of 2.3 nM .

HY-P3929

PKI (14-24)amide	PKA	Cancer
PKI (14-24)amide is a potent *PKA* inhibitor. PKI (14-24)amide strongly inhibited cyclic AMP-dependent protein kinase activity in the cell homogenate .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-121197

Balanol Ophiocordin; Azepinostatin	Structural Classification Natural Products Microorganisms Source Classification	MARCKS PKA PKC
Balanol (Ophiocordin; Azepinostatin) is a potent and ATP competitive *PKC/PKA* inhibitor against human PKC isozymes α, β-I, β-II, γ, δ, ε, η (IC₅₀s=4-9 nM) and ζ (IC₅₀=150 nM). Balanol also blocks the phosphorylation of cyclic AMP response element-binding protein (CREB) and myristoylated alanine-rich C kinase substrate (MARCKS). Balanol can be isolated from the fungus Verticillium balanoides .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.

PKA+inhibitor

Inhibitors & Agonists

Biochemical Assay Reagents

Peptides

NaturalProducts

Natural
Products